CDK 4/6 Inhibitor palbociclib (PD0332991) in Rb⁺ advanced breast cancer: Phase II activity, safety, and predictive biomarker assessment

Angela DeMichele, Amy S. Clark, Kay See Tan, Daniel F. Heitjan, Kristi Gramlich, Maryann Gallagher, Priti Lal, Michael Feldman, Paul Zhang, Christopher Colameco, David Lewis, Melissa Langer, Noah Goodman, Susan Domchek, Keerthi Gogineni, Mark Rosen, Kevin Fox, Peter O'Dwyer